Sanofi expects its infant RSV shot to roll out in the U.S. before respiratory virus season this fall, a company spokesperson said Friday.
The Food and Drug Administration on Monday approved Beyfortus, a monoclonal antibody that is administered as a single dose to infants before or during their first respiratory syncytial virus season.
The Sanofi spokesperson said the company does not expect any challenges with manufacturing or capacity to meet demand this RSV season.
Sanofi is working with the panel to place Beyfortus on the U.S. childhood immunization schedule, the company spokesperson said.
Nearly 100 infants die every year in the U.S. from the virus, according to a study last year.
Persons:
Sanofi, Beyfortus, Biden
Organizations:
Drug Administration, Sanofi, AstraZeneca, Centers for Disease Control, Children
Locations:
U.S, French, England